September 05, 2016 – InvitroCue (ASX:IVQ) has been awarded a tender by the Institute of Bioengineering and Nanotechnology, Agency for Science, Technology and Research (A*STAR), to supply and deliver Hepatocue 96-well plates and 3D-Cellusponge 96-well plates.
A*STAR will be utilizing InvitroCue’s technologies to advance research on non-animal approaches to chemical safety testing under an international collaboration with the US Environmental Protection Agency.
– ENDS –
For more information, please contact:
Matthew Gregorowski, Citadel-MAGNUS
T: +61 2 8234 0100
InvitroCue is a leading provider of bio-analytic solutions including in vitro cell-based testing technologies and image analytics software for use in digital pathology. InvitroCue has developed a unique 3D cell-based scaffolding technology that recapitulates in vivo human liver in the field of infectious diseases. The technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs and drive clinical decision support making for individual patients (personalised medicine).
InvitroCue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). InvitroCue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.
InvitroCue currently operates in Singapore and China and is listed on Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com
About A* STAR Liver Toxicity Project
This project will use 3D liver models developed at IBN and computational tools at the NCCT to identify novel predictive biomarkers of human liver toxicity to overcome limitations in existing 2D model tests, which limit their sensitivity, especially over extended periods. Machine learning approaches will be used to analyse and improve existing predictive models of acute and sub-acute liver toxicity. Source: Agency for Science, Technology and Research, 2016